In 2019 the pharmaceutical industry saw several large buyouts, including Bristol-Myers Squibb’s $74 billion purchase of Celgene, and AbbVie’s plan to acquire Allergan in a cash and stock deal valued at $63 billion.
But next year, the industry will probably go after single drugs as “bolt-ons,” according to Barry Cohen, an investment guru with 40 years experience in senior positions at large pharma companies, including Abbott and Bayer.
One example of a bolt-on, or relatively smaller deal, is Amgen’s recent $13.4 billion acquisition of Celgene’s psoriasis drug Otezla.
The trend toward these smaller purchases is a result of several factors, including that major pharmaceutical companies have seen slow growth or even a decline in stock prices as well as more antitrust scrutiny, according to the report. The threat of new competition and loss of patent protection also may contribute to the trend of smaller deals, Mr. Cohen wrote.
Read the full report here.
More articles on pharmacy:
Amazon’s PillPack seeking to win over new insurers in 2020
Roche buys international rights to Sarepta’s Duchenne drug for $750M
Former Aegerion sales rep defrauded insurers, stole identities to push cholesterol drug
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.